Method for predicting response of esophagus cancer to anti-ERBB3 antibody therapy, and kit
US11834716B2 · kind B2 · utility
0Cited by
2References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 12, 2018 |
| Grant date | Dec 5, 2023 |
| Priority date | — |
| Expiry date | Apr 13, 2040 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/485
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Disclosed is a method for predicting whether esophageal cancer is sensitive or resistant to treatment with an ERBB3 inhibitor, e.g, an anti-ERBB3 antibody. Specifically, the method predicts by measurement of expression at the RNA level, or at the protein level, of at least one biomarker selected from SDC2, PTGES, NCF2, NOXA1, CARD6 and GNAZ in a tumor sample.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.